<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02575456</url>
  </required_header>
  <id_info>
    <org_study_id>JSVCT024</org_study_id>
    <nct_id>NCT02575456</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine</brief_title>
  <official_title>A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Cansino Biotechnology Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Province Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and&#xD;
      Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV)&#xD;
      in Healthy Adults Aged Between 18 and 50 years in Sierra Leone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of solicited adverse reactions after vaccination</measure>
    <time_frame>7 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ELISA antigen-specific assays for antibody to GP responses</measure>
    <time_frame>14 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ELISA antigen-specific assays for antibody to GP responses</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ELISA antigen-specific assays for antibody to GP responses</measure>
    <time_frame>168 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse reactions after vaccination</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse reaction during the whole follow-up period</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-vaccination Rate of infected with HIV</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers response to human Ad5</measure>
    <time_frame>14 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers response to human Ad5</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers response to human Ad5</measure>
    <time_frame>168 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Ebola Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(4×10^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10^10 vp/vial), one shot in each arm, total dose of 1.6×10^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(4×10^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10^10vp/vial), total dose of 8×10^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ebola Vaccine</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>control</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged between 18 and 50 years&#xD;
&#xD;
          -  Able to understand the content of informed consent and signed the informed consent&#xD;
&#xD;
          -  Able and willing to complete all the secluded study process during the whole study&#xD;
             follow-up period (about 6 months).&#xD;
&#xD;
          -  Negative in HIV diagnostic blood test on day of enrollment&#xD;
&#xD;
          -  Axillary temperature ≤37.0°C on the day of enrollment&#xD;
&#xD;
          -  Non-pregnant females with a negative result in the urine pregnancy test on day of&#xD;
             enrollment&#xD;
&#xD;
          -  General good health as established by medical history and physical examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infected by Ebola virus (inquiry)&#xD;
&#xD;
          -  Vaccination with other Ebola vaccine (inquiry)&#xD;
&#xD;
          -  HIV infection or other serious immunodeficiency disease (inquiry)&#xD;
&#xD;
          -  Allergic history of any vaccination or drugs, or allergic to any ingredient of the&#xD;
             Ad5-EBOV, such as mannitol&#xD;
&#xD;
          -  Family history of brain or mental disease&#xD;
&#xD;
          -  Woman who is pregnant or breast-feeding&#xD;
&#xD;
          -  Any acute fever disease or infections in last 7 days&#xD;
&#xD;
          -  Major congenital defects or not well-controlled chronic illness&#xD;
&#xD;
          -  Asplenia or functional asplenia&#xD;
&#xD;
          -  Platelet disorder or other bleeding disorder&#xD;
&#xD;
          -  Faint at the sight of blood or needles.&#xD;
&#xD;
          -  Prior administration of immunodepressant or corticosteroids, antianaphylaxis&#xD;
             treatment, cytotoxic treatment in last 6 months&#xD;
&#xD;
          -  Prior administration of other research medicines in last 1 month&#xD;
&#xD;
          -  Prior administration of attenuated vaccine(s) in the last one month&#xD;
&#xD;
          -  Prior administration of inactivated vaccine(s) in the last 14 days&#xD;
&#xD;
          -  Any condition that in the opinion of the investigators may interfere with the&#xD;
             participants' compliance or evaluation of study objectives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alie H Wurie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health &amp; Sanitation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Alie H Wurie</name>
      <address>
        <city>Freetown</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sierra Leone</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>October 11, 2015</study_first_submitted>
  <study_first_submitted_qc>October 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

